Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

NCT05597202 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether stem cell treatment can reduce inflammation in the arteries of people with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 22 people Planned (estimated).

Who can join Ages 50+ · all sexes

Timeline Started 2023-01 · est. completion 2024-04

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT05597202 ↗

Description as written by the study sponsor.

To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.

Treatments tested

Semaglutide, 2.0 mg/mL Drug

Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.

Main thing measured	Difference in coronary 68Ga-Dotatate uptake after treatment.
Sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05597202 ↗